Combination of 177Lu-PSMA-617 and External Radiotherapy for the Treatment of Cerebral Metastases in Patients With Castration-Resistant Metastatic Prostate CancerWei, Xiao MD; Schlenkhoff, Carl MD; Schwarz, Bettina MD; Essler, Markus MD; Ahmadzadehfar, Hojjat MD, MScClinical Nuclear Medicine: September 2017 - Volume 42 - Issue 9 - p 704–706 doi: 10.1097/RLU.0000000000001763 Interesting Images Buy Abstract Author InformationAuthors Article MetricsMetrics Two castration-resistant prostate cancer patients, both with cerebral and visceral and lymphatic metastases, received multiple cycles of 177Lu-PSMA-617 treatments. The prognosis of both cases is dependent on brain metastases. Between 177Lu-PSMA-617 treatment cycles, local radiotherapy was also applied to the brain metastases. Prior to the combined therapy, all systemic metastases, including cerebral lesions, showed PSMA expression using 68Ga-PSMA PET/CT. Under the combined therapy, all the metastases, particularly the cerebral lesions, showed significant regression in size and PSMA expression over time. From the Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany. Received for publication March 29, 2017; revision accepted June 9, 2017. Conflicts of interest and sources of funding: none declared. Correspondence to: Hojjat Ahmadzadehfar, MD, MSc, Department of Nuclear Medicine, University Hospital Bonn, Sigmund-Freud-Str. 25, 53127 Bonn, Germany. E-mail: email@example.com; firstname.lastname@example.org. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.